Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pak Fah Yeow InternationalHKSE:00239 +0.64%80 Return-on-Tangible-Equity is 14.52% as of Dec. 2025, which is 90% above its 10-year median of 7.66. GuruFocus rates HKSE:00239 with a GF Score™ of 80/100 and a GF Value™ of HK$2.17 (Fairly Valued). The stock has 2 warning signs investors should review. Among 899 Drug Manufacturers companies, Pak Fah Yeow International ranks better than 65.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Pak Fah Yeow International's annualized net income for the quarter that ended in Dec. 2025 was HK$103.2 Mil. Pak Fah Yeow International's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$711.0 Mil. Therefore, Pak Fah Yeow International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 14.52%.
The historical rank and industry rank for Pak Fah Yeow International's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:00239'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.37 Med: 7.66 Max: 14.9
Current: 12.74
During the past 13 years, Pak Fah Yeow International's highest Return-on-Tangible-Equity was 14.90%. The lowest was -5.37%. And the median was 7.66%.
HKSE:00239's Return-on-Tangible-Equity is ranked better than 65.29% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs HKSE:00239: 12.74
Pak Fah Yeow International (HKSE:00239) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Pak Fah Yeow International Return-on-Tangible-Equity Related Terms
Pak Fah Yeow International Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pak Fah Yeow International Return-on-Tangible-Equity Chart
HKSE:00239 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pak Fah Yeow International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pak Fah Yeow International Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pak Fah Yeow International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Pak Fah Yeow International's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.52% mean?
Pak Fah Yeow International (HKSE:00239) has a Return-on-Tangible-Equity of 14.52% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pak Fah Yeow International and its competitors. This is 90% above median its historical median of 7.66. According to the industry distribution chart, Pak Fah Yeow International ranks #312 out of 899 companies in the Drug Manufacturers industry, placing it in the top 34.7%.
Is Pak Fah Yeow International's Return-on-Tangible-Equity too high?
Pak Fah Yeow International's current Return-on-Tangible-Equity of 14.52% is 90% above median its 10-year median of 7.66. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Pak Fah Yeow International's value of 14.52% is 84.5% above this industry median. Based on the distribution chart, Pak Fah Yeow International ranks #312 out of 899 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pak Fah Yeow International has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pak Fah Yeow International's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pak Fah Yeow International ranks #312 out of 899 companies for Return-on-Tangible-Equity. This puts Pak Fah Yeow International in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Pak Fah Yeow International's value of 14.52% is 84.5% above this benchmark. While the company's 10-year median is 7.66 vs. the industry median of 7.87, Pak Fah Yeow International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pak Fah Yeow International's current Return-on-Tangible-Equity of 14.52% is 84.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Pak Fah Yeow International and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pak Fah Yeow International's current Return-on-Tangible-Equity is 14.52%, which is 90% above median its own 10-year median of 7.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pak Fah Yeow International stock overvalued right now?
Based on GuruFocus' analysis, Pak Fah Yeow International (HKSE:00239) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.17, compared to a current price of HK$2.35 — trading 8.3% above its estimated fair value. The current Return-on-Tangible-Equity is 14.52%, which is 90% above median its 10-year median of 7.66 and 84.5% above the Drug Manufacturers industry median of 7.87. Pak Fah Yeow International's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Pak Fah Yeow International (HKSE:00239), the current Return-on-Tangible-Equity is 14.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pak Fah Yeow International (HKSE:00239) Overvalued in 2026?
Based on GuruFocus' analysis, Pak Fah Yeow International stock appears to be overvalued.
The current stock price of HK$2.35 is trading 8.3% above its estimated GF Value™ of HK$2.17.
GuruFocus considers Pak Fah Yeow International to be Fairly Valued.
Key valuation signals for HKSE:00239:
Return-on-Tangible-Equity: 14.52% (90% above median its 10-year median of 7.66)
GF Value™: HK$2.17 vs. price of HK$2.35 (8.3% above fair value)
Industry Position: 84.5% above the Drug Manufacturers median (#312 of 899)
No single metric tells the full story. See the HKSE:00239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pak Fah Yeow International Ltd, with its subsidiaries, is engaged in the manufacture and distribution of healthcare products, including Hoe Hin branded products. It also engages in real estate investment and treasury investment businesses. It has three business segments, namely healthcare, property investments, and treasury investments. The Company derives the majority of its revenues from the Healthcare segment.The Groups businesses cover Hong Kong, Macau, other regions in the Peoples Republic of China (the PRC or Chinese Mainland), Southeast Asia, North America and the United Kingdom.
80GF Score
Get the complete analysis for HKSE:00239
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00239 has been successfully added to your 
